Stockreport

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]

Cybin Inc.  (HELP) 
PDF closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development [1] . The sector is shedding its cou [Read more]